Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
NCT07497399 on ClinicalTrials.gov · last registry update 2026-07-17
Recruiting now, toward 120 participants. Due to report January 2030, alongside 7 other tracked readouts that quarter. Primary outcome, as filed: Change in normalized (for head size) brain parenchymal volume (nBPV). Sponsors move these dates routinely; any movement since this site started watching is listed below.
- Status
- RECRUITING
- Phase
- P2
- Drug
- exenatideBydureon, Byetta
- Sponsor
- Johns Hopkins University
- Sponsor type
- Other
- Enrollment
- 120
- Started
- 2026-04-28
- Primary completion
- 2030-01 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in normalized (for head size) brain parenchymal volume (nBPV)
Conditions studied
Multiple Sclerosis
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.